Close

Anti-MLANA T cell receptor ((α24β17)-2), pCDTCR1 (TCR-YC0703)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This TCR, α24β17, bound to A2-ELA with an affinity 30,000 times stronger than the natural parent MEL5 TCR, resulting in picomolar levels of binding. Comparison of the crystallographic structure of the α24β17 TCR and wild type MEL5 TCR in complex with A2-ELA showed that this remarkable enhancement in binding was attributable to new or altered contacts with the MHC protein.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • MLANA
  • Target Species
  • Human
  • Epitope
  • ELAAIGILTV
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-A*02:01
  • Targeting Diseases
  • Melanoma
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • α24β17
  • Host Species
  • Human

Target

  • Introduction
  • MLANA (Melan-A) is a Protein Coding gene. Diseases associated with MLANA include Melanoma and Microphthalmia. Among its related pathways are NF-kappaB Signaling.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-MLANA T cell receptor ((α24β17)-2), pCDTCR1 (TCR-YC0703). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.